BioLineRx (BLRX) Short Interest Ratio & Short Volume $0.22 -0.01 (-3.98%) (As of 05:36 PM ET) Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends BioLineRx Short Interest DataBioLineRx (BLRX) has a short interest of 827,800 shares. This marks a -10.21% decrease in short interest from the previous month. The short interest ratio (days to cover) is 0.8, indicating that it would take 0.8 days of the average trading volume of 518,799 shares to cover all short positions.Current Short Interest827,800 sharesPrevious Short Interest921,900 sharesChange Vs. Previous Month-10.21%Dollar Volume Sold Short$186,172.22Short Interest Ratio0.8 Days to CoverLast Record DateDecember 15, 2024Outstanding Shares79,939,000 sharesPercentage of Shares Shorted1.04%Today's Trading Volume2,140,340 sharesAverage Trading Volume518,799 sharesToday's Volume Vs. Average413% Short Selling BioLineRx? Sign up to receive the latest short interest report for BioLineRx and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartBLRX Short Interest Over TimeBLRX Days to Cover Over TimeBLRX Percentage of Float Shorted Over Time Ad DTI[PDF] The Opportunity in GoldCommodities expert, Geof Smith, insists that the supercycle on gold is just getting warmed up. In fact, even though gold looks like this since he initially called a major bull run 11 months ago… He’s still predicting it will be the TOP trade of 2025. His free eBook explains why You see, the last time gold launched into a supercycle like this it surged 536% The time before that was over 1,000%... That’s why Geof released this urgent guide to help you. Most people think they’ve missed out, but he thinks we’re at the very beginning of what could be the largest gold rally of our lifetimes. But, believe it or not, Geof doesn’t think you should just buy and hold precious metals. He’ll share more about his approach inside the eBook and it might surprise you.Tap here to read it BioLineRx Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 12/15/2024827,800 shares $186,172.22 -10.2%N/A0.8 $0.22 11/30/2024921,900 shares $276,570.00 -16.2%N/A1.1 $0.30 11/15/20241,100,000 shares $523,160.00 +3.8%N/A1.6 $0.48 10/31/20241,060,000 shares $434,600.00 +70.6%N/A3.5 $0.41 10/15/2024621,400 shares $271,924.64 +351.3%N/A2.2 $0.44 9/30/2024137,700 shares $73,820.97 -23.2%N/A0.5 $0.54 Get the Latest News and Ratings for BLRX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for BioLineRx and its competitors with MarketBeat's FREE daily newsletter. 9/15/2024179,200 shares $111,301.12 +28.7%N/A0.7 $0.62 8/31/2024139,200 shares $90,048.48 -47.9%N/A0.5 $0.65 8/15/2024267,200 shares $181,241.76 -3.3%N/A0.8 $0.68 7/31/2024276,400 shares $217,084.56 +130.9%N/A0.8 $0.79 7/15/2024119,700 shares $90,972.00 -63.1%N/A0.3 $0.76 6/30/2024324,300 shares $184,818.57 +52.9%N/A0.9 $0.57 6/15/2024212,100 shares $141,661.59 -40.5%N/A0.5 $0.67 5/31/2024356,200 shares $265,582.72 +62.6%N/A0.8 $0.75 5/15/2024219,100 shares $135,173.75 -46.6%N/A0.5 $0.62 4/30/2024410,600 shares $274,855.64 -47.6%N/A1 $0.67 4/15/2024783,600 shares $504,560.04 +32.5%N/A1.8 $0.64 3/31/2024591,500 shares $662,480.00 +82.2%N/A1.6 $1.12 3/15/2024324,700 shares $373,405.00 +76.6%N/A1 $1.15 2/29/2024183,900 shares $244,587.00 -8.1%N/A0.6 $1.33 2/15/2024200,000 shares $221,000.00 -19.7%N/A0.7 $1.11 1/31/2024249,100 shares $296,429.00 -4.7%N/A0.8 $1.19 1/15/2024261,500 shares $368,715.00 +16.1%N/A0.8 $1.41 12/31/2023225,200 shares $353,564.00 +96.2%N/A0.6 $1.57 12/15/2023114,800 shares $182,532.00 -59.2%N/A0.3 $1.59 11/30/2023281,100 shares $407,595.00 -21.3%N/A0.3 $1.45 11/15/2023357,300 shares $603,837.00 -27.2%N/A0.3 $1.69 10/31/2023490,600 shares $735,900.00 -52.4%N/A0.4 $1.50 10/15/20231,030,000 shares $1.65 million -59.8%N/A0.9 $1.60 9/30/20232,560,000 shares $4.66 million -42.7%N/A2.2 $1.82 9/15/20234,470,000 shares $8.72 million +86.3%N/A4.1 $1.95 8/31/20232,400,000 shares $4.20 million +2.6%N/A2.6 $1.75 8/15/20232,340,000 shares $3.49 million +9.9%N/A6.2 $1.49 7/31/20232,130,000 shares $3.28 million -14.8%N/A4.9 $1.54 7/15/20232,500,000 shares $4.18 million +8.2%N/A5.6 $1.67 6/30/20232,310,000 shares $3.68 million +0.9%N/A4.9 $1.60 6/15/20232,290,000 shares $4.05 million +19.3%N/A4.6 $1.77 5/31/20231,920,000 shares $3.02 million -1.5%N/A3.8 $1.58 5/15/20231,950,000 shares $2.69 million +69.6%N/A4 $1.38 4/30/20231,150,000 shares $1.23 million +21.3%N/A3.1 $1.07Why I'm telling friends to avoid gold stocks (Ad)Back in November, gold made a tiny move of 1.6%. But according to my backtesting by using a special type of gold trade, I would have seen a 141% gain in just a week. It happened again in March. Gold nudged up 1.2%. This time? A 104% overnight gain. And in June? A 1% gold move turned into a 74% gain in two weeks. Granted, there would have been smaller wins and those that did not work out, but you see, there's a reason I'm telling all my friends to hold off from buying gold or regular gold stocks right now. There's a more lucrative way to play the gold market as we enter a new breakout period. It's all about catching what I call "Acceleration Cycles."And if you’d like to get your hands on this, here you go, the complete breakdown. 4/15/2023948,300 shares $1.04 million +70.6%N/A2.8 $1.10 3/31/2023556,000 shares $492,894.00 +546.5%N/A1.8 $0.89 3/15/202386,000 shares $52,374.00 +9.7%N/A0.3 $0.61 2/28/202378,400 shares $46,648.00 -64.7%N/A0.3 $0.60 2/15/2023222,100 shares $137,702.00 +97.3%N/A0.9 $0.62 1/31/2023112,600 shares $70,926.74 -42.1%N/A0.3 $0.63 1/15/2023194,600 shares $134,488.06 +9.8%N/A0.6 $0.69 12/30/2022177,200 shares $104,548.00 +22.6%N/A0.5 $0.59 12/15/2022144,500 shares $92,248.80 -11.1%N/A0.4 $0.64 11/30/2022162,500 shares $114,546.25 -37.6%N/A0.4 $0.70 11/15/2022260,200 shares $176,936.00 +7.3%N/A0.7 $0.68 10/31/2022242,500 shares $205,446.00 +33.4%N/A0.9 $0.85 10/15/2022181,800 shares $152,712.00 +127.8%N/A0.7 $0.84 9/30/202279,800 shares $73,815.00 -80.5%N/A0.3 $0.93 9/15/2022408,300 shares $649,197.00 +17.3%N/A1.9 $1.59 8/31/2022348,200 shares $529,264.00 -20.7%N/A2.7 $1.52 8/15/2022439,000 shares $838,490.00 +14.3%N/A3.5 $1.91 7/31/2022384,000 shares $506,880.00 -6.6%N/A2.8 $1.32 7/15/2022411,200 shares $551,008.00 +14.8%N/A2.7 $1.34 6/30/2022358,100 shares $458,368.00 +3.7%N/A2.2 $1.28 6/15/2022345,400 shares $466,290.00 -18.1%N/A2 $1.35 5/31/2022421,800 shares $658,008.00 -11.7%N/A2.3 $1.56 5/15/2022477,400 shares $572,880.00 +30.8%N/A2.3 $1.20 4/30/2022365,000 shares $445,300.00 -9.5%N/A1.8 $1.22 4/15/2022403,300 shares $621,082.00 -20.8%N/A2 $1.54 3/31/2022509,200 shares $870,732.00 -11.3%N/A2.1 $1.71 3/15/2022574,100 shares $878,373.00 +14.7%N/A2 $1.53 2/28/2022500,700 shares $761,064.00 -6.1%N/A1.2 $1.52 2/15/2022533,400 shares $938,784.00 +25.9%N/A1.2 $1.76 1/31/2022423,800 shares $771,316.00 +6.5%N/A0.9 $1.82 1/15/2022398,100 shares $800,181.00 +21.4%N/A0.9 $2.01 12/31/2021328,000 shares $669,120.00 +19.5%N/A0.6 $2.04 12/15/2021274,600 shares $648,056.00 +135.3%N/A0.6 $2.36 11/30/2021116,700 shares $306,921.00 -36.8%N/A0.3 $2.63 11/15/2021184,500 shares $527,670.00 +18.0%N/A0.5 $2.86 10/29/2021156,400 shares $444,176.00 -54.1%N/A0.4 $2.84 10/15/2021340,700 shares $1.04 million +65.3%N/A0.8 $3.06 9/30/2021206,100 shares $566,775.00 +8.5%N/A0.4 $2.75 9/15/2021190,000 shares $513,000.00 -34.7%N/A0.2 $2.70 8/31/2021291,000 shares $835,170.00 +5.0%N/A0.3 $2.87 8/13/2021277,100 shares $836,842.00 +3.2%N/A0.3 $3.02 7/30/2021268,500 shares $867,255.00 +228.2%N/A0.2 $3.23 7/15/202181,800 shares $273,212.00 -27.2%N/A0 $3.34 6/30/2021112,300 shares $315,563.00 -64.8%N/A0 $2.81 6/15/2021319,100 shares $890,289.00 -50.7%N/A0.1 $2.79 5/28/2021647,600 shares $1.85 million +15.8%N/A0.1 $2.86 5/14/2021559,500 shares $1.59 million +27.6%N/A0.1 $2.85 4/30/2021438,500 shares $1.34 million +9.3%N/A0.1 $3.05 4/15/2021401,200 shares $1.10 million -3.0%N/A0.3 $2.73 3/31/2021413,400 shares $1.17 million -7.0%N/A0.2 $2.82Why I'm telling friends to avoid gold stocks (Ad)Back in November, gold made a tiny move of 1.6%. But according to my backtesting by using a special type of gold trade, I would have seen a 141% gain in just a week. It happened again in March. Gold nudged up 1.2%. This time? A 104% overnight gain. And in June? A 1% gold move turned into a 74% gain in two weeks. Granted, there would have been smaller wins and those that did not work out, but you see, there's a reason I'm telling all my friends to hold off from buying gold or regular gold stocks right now. There's a more lucrative way to play the gold market as we enter a new breakout period. It's all about catching what I call "Acceleration Cycles."And if you’d like to get your hands on this, here you go, the complete breakdown. 3/15/2021444,600 shares $1.35 million -34.2%N/A0.2 $3.03 2/26/2021675,400 shares $2.18 million -62.5%N/A0.3 $3.23 2/12/20211,800,000 shares $6.68 million +0.6%N/A0.7 $3.71 1/29/20211,790,000 shares $5.24 million -27.8%N/A0.7 $2.93 1/15/20212,480,000 shares $6.94 million +0.8%N/A0.4 $2.80 12/31/20202,460,000 shares $6.27 million -2.4%N/A0.4 $2.55 12/15/20202,520,000 shares $8.54 million +11.5%N/A0.5 $3.39 11/30/20202,260,000 shares $5.24 million -8.9%N/A0.5 $2.32 11/15/20202,480,000 shares $5.83 million +79.7%N/A0.5 $2.35 10/30/20201,380,000 shares $2.04 million -8.0%N/A0.3 $1.48 10/15/20201,500,000 shares $2.41 million No ChangeN/A6.1 $1.61 9/30/20201,500,000 shares $2.46 million -1.3%N/A4.5 $1.64 9/15/20201,520,000 shares $2.64 million -1.3%N/A4.2 $1.74 8/31/20201,540,000 shares $2.80 million -7.2%N/A3.5 $1.82 8/14/20201,660,000 shares $3.40 million +12.2%N/A2.3 $2.05 7/31/20201,480,000 shares $3.36 million +114.6%N/A2.1 $2.27 7/15/2020689,800 shares $1.22 million +60.2%N/A1.1 $1.77 6/30/2020430,600 shares $736,326.00 +7.3%N/A0.8 $1.71 6/15/2020401,200 shares $649,944.00 +432.8%N/A0.8 $1.62 5/29/202075,300 shares $146,082.00 +2.5%N/A0.2 $1.94 5/15/202073,500 shares $118,335.00 +25.6%N/A0.4 $1.61 4/30/202058,500 shares $98,280.00 -5.8%N/A0.9 $1.68 4/15/202062,100 shares $108,414.18 +37.4%N/A0.9 $1.75 3/31/202045,200 shares $71,416.00 -14.7%N/A0.6 $1.58 3/13/202053,000 shares $89,570.00 -19.7%N/A1.1 $1.69 2/28/202066,000 shares $77,880.00 -9.1%N/A0.4 $1.18 2/14/202072,600 shares $125,598.00 -51.0%N/A0.4 $1.73 1/31/2020148,200 shares $271,206.00 -34.9%N/A0.8 $1.83 1/15/2020227,500 shares $495,950.00 -6.7%N/A1.2 $2.18 12/31/2019243,700 shares $633,620.00 +33.8%N/A1.3 $2.60 BLRX Short Interest - Frequently Asked Questions What is BioLineRx's current short interest? Short interest is the volume of BioLineRx shares that have been sold short but have not yet been covered or closed out. As of December 15th, traders have sold 827,800 shares of BLRX short. Learn More on BioLineRx's current short interest. What is a good short interest ratio for BioLineRx? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. BLRX shares currently have a short interest ratio of 1.0. Learn More on BioLineRx's short interest ratio. Is BioLineRx's short interest increasing or decreasing? BioLineRx saw a decline in short interest during the month of December. As of December 15th, there was short interest totaling 827,800 shares, a decline of 10.2% from the previous total of 921,900 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does BioLineRx's short interest compare to its competitors? Here is how the short interest of companies in the industry of "pharmaceutical products" compare to BioLineRx: Prelude Therapeutics Incorporated (14.99%), BeyondSpring Inc. (8.38%), SELLAS Life Sciences Group, Inc. (10.60%), OptiNose, Inc. (2.11%), PDS Biotechnology Co. (11.31%), Cue Biopharma, Inc. (1.70%), Janone Inc. (0.97%), Annovis Bio, Inc. (11.31%), Immix Biopharma, Inc. (2.44%), RAPT Therapeutics, Inc. (4.92%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: AppLovin Co. ($5.70 billion), Charter Communications, Inc. ($4.32 billion), Spotify Technology S.A. ($4.06 billion), Canadian Natural Resources Limited ($3.45 billion), Reddit, Inc. ($2.79 billion), International Paper ($2.70 billion), Cencora, Inc. ($2.27 billion), SoFi Technologies, Inc. ($2.21 billion), Lululemon Athletica Inc. ($2.13 billion), and Rivian Automotive, Inc. ($2.05 billion). View all of the most shorted stocks. What does it mean to sell short BioLineRx stock? Short selling BLRX is an investing strategy that aims to generate trading profit from BioLineRx as its price is falling. BLRX shares are trading down $0.01 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against BioLineRx? A short squeeze for BioLineRx occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of BLRX, which in turn drives the price of the stock up even further. How often is BioLineRx's short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including BLRX, twice per month. The most recent reporting period available is December, 15 2024. More Short Interest Resources from MarketBeat Related Companies PRLD Short Interest BYSI Short Interest SLS Short Interest OPTN Short Interest PDSB Short Interest CUE Short Interest ALTS Short Interest ANVS Short Interest IMMX Short Interest RAPT Short Interest Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:BLRX) was last updated on 12/26/2024 by MarketBeat.com Staff From Our PartnersURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredThe #1 Coin for November 2024Grayscale Investments just announced a new fund offering access to a HOT new DeFi coin… And thanks to this ...Crypto 101 Media | SponsoredI was wrong. Dead wrong. Something is stirring deep in Silicon Valley. My team and I have been watching the tech markets closely. ...Porter & Company | SponsoredTSLA *BANG* incoming (bullet in the chamber rn)I just pinpointed 5 dirt-cheap stocks that could soar the second the shot goes off. Thanks to Donald Trump’...StocksToTrade | SponsoredBuy this Stock before Trump Takes Office!To make sure everyone has the opportunity to get in, closes for good at midnight on January 1st, we're lowerin...Behind the Markets | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioLineRx Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioLineRx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
